## Table S1: Number of participants/missing data

Total number of ADD participants with baseline inflammatory and clinical data			Total TRD 143	<b>Controls</b> 31
	Metyrapone	Placebo	Total TRD	Controls
Total numbers after exclusions for inflammatory conditions <sup>a</sup>	63	66	129	28
Number after exclusion of non-adherent metyrapone patients <sup>b</sup>	40	66	106	-
Number of participants (excluding metyrapone non-adherent) with clinical and inflammatory outcome data <sup>c</sup>	40	57	97	-

<sup>a</sup> included in baseline patient/control comparisons, and the mITT moderation and mediation analyses

<sup>b</sup> included in per-protocol moderation and mediation analyses

<sup>c</sup> included in analyses with missing data addressed using full information maximum likelihood






Figure a-d: Patients' and controls' baseline levels of

- **a**) IL-6
- b) TNFa
- c) CRP
- **d**) IL-10

Log transformed mean values of the cytokines assessed are presented. Error bars represent standard deviation (SD). CRP = C-reactive Protein; IL-6 = Interleukin 6; IL-10 = Interleukin 10; TNF- $\alpha$  = Tumour Necrosis Factor  $\alpha$ .






Figure A / B: IL-6 associations with treatment group and clinical outcome, as examined in linear regression and mediation analysis

- a) Pre-treatment IL-6 as a predictor of subsequent clinical outcome
- b) Change in IL-6 during treatment and association with clinical outcome